Race Oncology
Race Oncology is a specialty pharmaceutical company focused on rediscovering and rescuing life-saving drugs that can deliver early commercial milestones. Race Oncology’s first asset is Bisantrene, a small molecule Chemotherapy drug that has been evaluated clinically for Acute Myeloid Leukaemia (AML).
ASX Announcements
| Date | Title | |
|---|---|---|
| 17/05/2018 | Notice of General Meeting/Proxy Form | Download |
| 15/05/2018 | Race appoints Oncologist to head Medical Affairs | Download |
| 15/05/2018 | Race executes agreement for Bisantrene clinical trial | Download |
| 07/05/2018 | Interview with Dr John Cullity | Download |
| 30/04/2018 | Investor Update | Download |
| 27/04/2018 | Appendix 3Y-Bill Garner | Download |
| 20/04/2018 | Appendix 4C - quarterly | Download |
| 13/04/2018 | Appendix 3B | Download |
| 13/04/2018 | Cleansing Notice | Download |
| 11/04/2018 | Race signs global distribution agreement with Durbin PLC | Download |
ASX: RAC
Price
Latest News
Proactive Investor interviews John Cullity
Race Oncology Non-Executive Director Dr. John Cullity speaks with Proactive Investors about the
New director upbeat about Race Oncology’s growth prospects
New Race non-executive director Dr John Cullity has used his first interview to highlight the
Agreement signals new market opportunities for Race
Race Oncology has announced it has executed a global distribution agreement with UK-based,
Don't miss important updates
Get the latest news & announcement and stay up-to-date.